

H-P Hartung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2689009/publications.pdf>

Version: 2024-02-01

310
papers

39,144
citations

10984

71
h-index

2828

191
g-index

316
all docs

316
docs citations

316
times ranked

25432
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 429-440.	3.0	40
2	AQP4-IgG-seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	2.0	16
3	CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	4
4	Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , 2022, 145, 887-896.	7.6	16
5	Body mass index as a predictor of MS activity and progression among participants in BENEFIT. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1277-1285.	3.0	12
6	Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimodâ€”potentials and risks of subsequent highly active agents. <i>Journal of Neurology</i> , 2022, 269, 2806-2818.	3.6	5
7	Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 192-202.	5.3	17
8	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. <i>Clinical Neurophysiology</i> , 2022, 138, 231-240.	1.5	7
9	Analysis of relapse by inflammatory Raschâ€”built overall disability scale status in the <sc>PATH</sc> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 159-165.	3.1	3
10	The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis. <i>Brain Stimulation</i> , 2022, 15, 403-413.	1.6	6
11	Eculizumab versus rituximab in generalised myasthenia gravis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 548-554.	1.9	19
12	Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	23
13	Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. <i>Neurotherapeutics</i> , 2022, 19, 753-773.	4.4	14
14	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	10.1	27
15	The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. <i>Neurotherapeutics</i> , 2022, 19, 864-873.	4.4	16
16	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€”Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	64
17	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 978-985.	1.9	17
18	Tissue donations for multiple sclerosis research: current state and suggestions for improvement. <i>Brain Communications</i> , 2022, 4, fcac094.	3.3	4

#	ARTICLE	IF	CITATIONS
19	The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 3937-3958.	3.6	14
20	031â€¦ Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A23.1-A23.	1.9	0
21	Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. <i>Current Opinion in Neurology</i> , 2022, 35, 319-327.	3.6	12
22	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€‰years of follow-up in the DAYBREAK open-label extension trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1944-1962.	3.0	16
23	Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2379-2389.	3.6	26
24	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021, 27, 479-482.	3.0	7
25	Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. <i>Clinical Neurophysiology</i> , 2021, 132, 226-231.	1.5	4
26	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021, 89, 13-23.	5.3	123
27	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102673.	2.0	20
28	Long-term adherence and response to botulinum toxin in different indications. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 15-28.	3.7	11
29	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110396.	3.5	86
30	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	3.5	11
31	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.0	11
32	Consequences of COVID-19 pandemic lockdown on emergency and stroke care in a German tertiary stroke center. <i>Neurological Research and Practice</i> , 2021, 3, 21.	2.0	5
33	Neuroprotective Properties of 4-Aminopyridine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	22
34	Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence. <i>EBioMedicine</i> , 2021, 65, 103276.	6.1	17
35	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	20
36	Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy. <i>Journal of Neuroinflammation</i> , 2021, 18, 89.	7.2	15

#	ARTICLE	IF	CITATIONS
37	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Multiple Sclerosis and Related Disorders, 2021, 49, 102695.	2.0	5
38	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology, 2021, 97, 68-79.	1.1	96
39	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
40	Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making. Annals of Neurology, 2021, 89, 1084-1087.	5.3	0
41	Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	12
42	Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. Current Opinion in Neurology, 2021, 34, 598-603.	3.6	16
43	Type O blood group associates with higher anti-EBV polyomavirus antibody levels. Brain and Behavior, 2021, 11, e2298.	2.2	3
44	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 839-850.	2.5	2
45	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1033-1043.	1.9	26
46	Microglia contributes to remyelination in cerebral but not spinal cord ischemia. Glia, 2021, 69, 2739-2751.	4.9	9
47	Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1473-1476.	3.0	21
48	Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk. Neurotherapeutics, 2021, 18, 1654-1656.	4.4	1
49	Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Clinical Neurophysiology, 2021, 132, 2184-2190.	1.5	3
50	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
51	Targeting B Cells to Modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	37
52	Targeting B cells to modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	30
53	Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. CNS Drugs, 2021, 35, 1173-1188.	5.9	8
54	CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	24

#	ARTICLE	IF	CITATIONS
55	Relapse-independent multiple sclerosis progression under natalizumab. <i>Brain Communications</i> , 2021, 3, fcab229.	3.3	14
56	Semi-Automated Live Tracking of Microglial Activation in CX3CR1GFP Mice During Experimental Autoimmune Encephalomyelitis by Confocal Scanning Laser Ophthalmoscopy. <i>Frontiers in Immunology</i> , 2021, 12, 761776.	4.8	4
57	Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2123-2125.	3.0	1
58	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. <i>Frontiers in Immunology</i> , 2021, 12, 794075.	4.8	4
59	Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-Analysis. <i>Biomedicines</i> , 2021, 9, 1899.	3.2	2
60	Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. <i>Journal of Neurology</i> , 2020, 267, 308-316.	3.6	12
61	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 113-121.	1.9	34
62	Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. <i>European Journal of Neurology</i> , 2020, 27, 196-203.	3.3	11
63	Big data in MS—What can we learn from large international observational studies such as MSBase?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 4-5.	3.0	2
64	Heterogeneous fate choice of genetically modulated adult neural stem cells in gray and white matter of the central nervous system. <i>Glia</i> , 2020, 68, 393-406.	4.9	4
65	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020, 26, 296-310.	6.7	178
66	NK cell markers predict the efficacy of IV immunoglobulins in CIDP. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	8
67	Serum neurofilament light chain. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	25
68	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	10.2	64
69	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102492.	2.0	20
70	Neurological manifestations of severe acute respiratory syndrome coronavirus 2—a controversy—gone viral™. <i>Brain Communications</i> , 2020, 2, fcaa149.	3.3	7
71	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <scp>PATH</scp> study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 230-237.	3.1	15
72	Prolonged Neuropsychological Deficits, Central Nervous System Involvement, and Brain Stem Affection After COVID-19—A Case Series. <i>Frontiers in Neurology</i> , 2020, 11, 574004.	2.4	20

#	ARTICLE	IF	CITATIONS
73	Comparison of different optomotor response readouts for visual testing in experimental autoimmune encephalomyelitis-optic neuritis. <i>Journal of Neuroinflammation</i> , 2020, 17, 216.	7.2	10
74	Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia. <i>Frontiers in Neurology</i> , 2020, 11, 661.	2.4	7
75	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	7.6	56
76	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 998-1009.	10.2	98
77	Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients. <i>BMC Neurology</i> , 2020, 20, 333.	1.8	2
78	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 782.	2.4	6
79	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020, 56, 102807.	6.1	67
80	Ocrelizumab shorter infusion. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	21
81	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. <i>EBioMedicine</i> , 2020, 56, 102822.	6.1	17
82	Retinal Changes After Posterior Cerebral Artery Infarctions Display Different Patterns of the Nasal und Temporal Sector in a Case Series. <i>Frontiers in Neurology</i> , 2020, 11, 508.	2.4	3
83	Old and new breakthroughs in neuromyelitis optica. <i>Lancet Neurology</i> , The, 2020, 19, 280-281.	10.2	10
84	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, e1027-e1040.	1.1	28
85	4-Aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect “ Commentary. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1312-1314.	3.0	1
86	Capillary microscopy in Europeans with idiopathic Moyamoya angiopathy. <i>Microcirculation</i> , 2020, 27, e12616.	1.8	1
87	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	36
88	Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years “ case report. <i>BMC Neurology</i> , 2020, 20, 158.	1.8	18
89	Meeting report: “Human endogenous retroviruses: HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer“ Lyon, France, november 5th and 6th 2019 “ an MS scientist's digest. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102068.	2.0	4
90	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	7.6	29

#	ARTICLE	IF	CITATIONS
91	Alemtuzumab: Rare serious adverse events of a high-efficacy drug. <i>Multiple Sclerosis Journal</i> , 2020, 26, 737-740.	3.0	14
92	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. <i>Neurology</i> , 2020, 94, e1950-e1960.	1.1	45
93	Neuroprotective Properties of Dimethyl Fumarate Measured by Optical Coherence Tomography in Non-inflammatory Animal Models. <i>Frontiers in Neurology</i> , 2020, 11, 601628.	2.4	10
94	COVID-19 and management of neuroimmunological disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 347-348.	10.1	32
95	Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2020, 94, e2373-e2383.	1.1	67
96	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	8.4	31
97	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1255-1262.	3.0	37
98	The Molecular Basis for Remyelination Failure in Multiple Sclerosis. <i>Cells</i> , 2019, 8, 825.	4.1	71
99	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. <i>BMC Neurology</i> , 2019, 19, 190.	1.8	17
100	An unmet clinical need: roads to remyelination in MS. <i>Neurological Research and Practice</i> , 2019, 1, 21.	2.0	19
101	Drug Treatment of Clinically Isolated Syndrome. <i>CNS Drugs</i> , 2019, 33, 659-676.	5.9	12
102	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101335.	2.0	6
103	No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. <i>Frontiers in Neurology</i> , 2019, 10, 741.	2.4	3
104	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 845-856.	10.2	110
105	Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 290-295.	2.1	6
106	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2019, 16, 203.	7.2	28
107	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet</i> , The, 2019, 394, 1352-1363.	13.7	433
108	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1009-1020.	10.2	191

#	ARTICLE	IF	CITATIONS
109	The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis. <i>Brain</i> , 2019, 142, 2552-2555.	7.6	3
110	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e590.	6.0	37
111	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2019, 93, e1778-e1786.	1.1	37
112	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1021-1033.	10.2	184
113	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 48-55.	3.1	17
114	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 72-79.	3.1	13
115	pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15216-15225.	7.1	78
116	Clinical trials in multiple sclerosis: potential future trial designs. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984709.	3.5	10
117	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1273-1288.	3.0	29
118	CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography. <i>Annals of Neurology</i> , 2019, 85, 615-617.	5.3	3
119	Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	13
120	Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. <i>Journal of Neurology</i> , 2019, 266, 1421-1428.	3.6	29
121	Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 850.	9.0	39
122	Challenging a concept: Pulsed treatment regimenâ€”No risk of PML?. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1076-1078.	3.0	1
123	Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. <i>Neuroscience Letters</i> , 2019, 704, 116-125.	2.1	21
124	Misdiagnoses and delay of diagnoses in Moyamoya angiopathyâ€”a large Caucasian case series. <i>Journal of Neurology</i> , 2019, 266, 1153-1159.	3.6	28
125	Meningitis gone viral: description of the echovirus wave 2013 in Germany. <i>BMC Infectious Diseases</i> , 2019, 19, 1010.	2.9	8
126	Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2019, 32, 305-312.	3.6	62

#	ARTICLE	IF	CITATIONS
127	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. <i>Current Opinion in Neurology</i> , 2019, 32, 365-377.	3.6	73
128	Remyelination in multiple sclerosis: from concept to clinical trials. <i>Current Opinion in Neurology</i> , 2019, 32, 378-384.	3.6	28
129	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change. <i>Current Opinion in Neurology</i> , 2019, 32, 327-337.	3.6	32
130	Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism. <i>FASEB Journal</i> , 2019, 33, 4703-4715.	0.5	25
131	Monoclonal Antibodies for Multiple Sclerosis: An Update. <i>BioDrugs</i> , 2019, 33, 61-78.	4.6	21
132	Managing Risks with Immune Therapies in Multiple Sclerosis. <i>Drug Safety</i> , 2019, 42, 633-647.	3.2	18
133	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	2.3	22
134	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019, 92, e48-e54.	1.1	95
135	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1605-1617.	3.0	57
136	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 565-573.	3.0	9
137	Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. <i>Journal of Neurochemistry</i> , 2018, 146, 86-98.	3.9	26
138	A randomised, multicentre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 108-114.	3.1	14
139	ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 696-700.	3.0	4
140	Acute exacerbations after decades of non-active chronic multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1265-1266.	3.0	1
141	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 215-237.	3.3	147
142	Teriflunomide promotes oligodendroglial differentiation and myelination. <i>Journal of Neuroinflammation</i> , 2018, 15, 76.	7.2	37
143	Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. <i>Journal of Neuroinflammation</i> , 2018, 15, 71.	7.2	37
144	Case of alopecia universalis associated with alemtuzumab treatment in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, .	6.0	7

#	ARTICLE	IF	CITATIONS
145	Cerebrospinal fluid findings in reversible cerebral vasoconstriction syndrome: a way to differentiate from cerebral vasculitis?. <i>Clinical and Experimental Immunology</i> , 2018, 193, 341-345.	2.6	15
146	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876064.	1.0	32
147	Human Endogenous Retroviruses in Neurological Diseases. <i>Trends in Molecular Medicine</i> , 2018, 24, 379-394.	6.7	212
148	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	10.2	238
149	Human mesenchymal factors induce rat hippocampal and human neural stem cell dependent oligodendrogenesis. <i>Glia</i> , 2018, 66, 145-160.	4.9	22
150	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	10.2	193
151	Late age onset of amyotrophic lateral sclerosis is often not considered in elderly people. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 329-334.	2.1	17
152	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	7.6	190
153	Immune-mediated neuropathies. <i>Nature Reviews Disease Primers</i> , 2018, 4, 31.	30.5	92
154	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
155	Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1776-1778.	3.0	18
156	Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. <i>Journal of Neurology</i> , 2018, 265, 2425-2433.	3.6	23
157	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 689-698.	10.2	48
158	Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. <i>CNS Drugs</i> , 2018, 32, 637-651.	5.9	12
159	Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA bypass surgery in Europe—a retrospective analysis of 64 procedures. <i>Journal of Neurology</i> , 2018, 265, 2370-2378.	3.6	13
160	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 94-105.	3.0	95
161	Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2/HO-1 signaling pathway. <i>Acta Neuropathologica</i> , 2017, 133, 489-491.	7.7	20
162	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	3.1	89

#	ARTICLE	IF	CITATIONS
163	Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome. Journal of Neurology, 2017, 264, 799-801.	3.6	1
164	Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1092-1094.	1.9	17
165	Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Multiple Sclerosis Journal, 2017, 23, 920-922.	3.0	1
166	Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017. Multiple Sclerosis and Related Disorders, 2017, 15, 18-23.	2.0	4
167	Sodium intake and multiple sclerosis activity and progression in <scp>BENEFIT</scp>. Annals of Neurology, 2017, 82, 20-29.	5.3	80
168	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647.	1.9	123
169	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. Glia, 2017, 65, 1521-1534.	4.9	33
170	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 221-234.	27.0	1,322
171	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 209-220.	27.0	1,324
172	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731773280.	1.0	22
173	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188
174	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
175	Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. Drugs, 2017, 77, 1755-1768.	10.9	49
176	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology, 2017, 89, 1584-1593.	1.1	65
177	CIDP and other inflammatory neuropathies in diabetes " diagnosis and management. Nature Reviews Neurology, 2017, 13, 599-611.	10.1	73
178	Fulminant intramedullary spinal cord sarcoidosis. Multiple Sclerosis and Related Disorders, 2017, 18, 47-48.	2.0	2
179	Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Multiple Sclerosis Journal, 2017, 23, 1176-1178.	3.0	2
180	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. Journal of Neurology, 2017, 264, 1370-1380.	3.6	55

#	ARTICLE	IF	CITATIONS
181	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 909-914.	3.7	11
182	Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. <i>Frontiers in Neurology</i> , 2017, 8, 305.	2.4	14
183	Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patientsâ€”A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1749.	4.1	11
184	Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke. <i>PLoS ONE</i> , 2017, 12, e0190218.	2.5	27
185	Outcome and Treatment Effects in Stroke Associated with Acute Cervical ICA Occlusion. <i>PLoS ONE</i> , 2017, 12, e0170247.	2.5	28
186	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017, 12, e0170395.	2.5	34
187	Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. <i>PLoS ONE</i> , 2017, 12, e0189701.	2.5	26
188	Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. <i>BMJ Open Ophthalmology</i> , 2016, 1, e000008.	1.6	9
189	Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 63.	3.7	6
190	Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. <i>Journal of Neuroinflammation</i> , 2016, 13, 143.	7.2	21
191	CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation. <i>PLoS ONE</i> , 2016, 11, e0146503.	2.5	18
192	Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with <i>Candida utilis</i> Expressing the Immunogenic MOG35-55 Peptide. <i>PLoS ONE</i> , 2016, 11, e0155082.	2.5	12
193	Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 199-204.	3.6	40
194	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 1089.	9.0	92
195	Fampridineâ€”PR (prolonged released 4â€”aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 85-87.	3.1	8
196	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	1.9	228
197	Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. <i>Journal of Neurology</i> , 2016, 263, 1418-1426.	3.6	42
198	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1386-1396.	3.0	118

#	ARTICLE	IF	CITATIONS
199	Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of “Chinese restaurant syndrome”. <i>Journal of Neurology</i> , 2016, 263, 1027-1028.	3.6	2
200	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016, 87, 1985-1992.	1.1	55
201	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 345.	1.6	21
202	Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. <i>Molecular Neurodegeneration</i> , 2016, 11, 53.	10.8	13
203	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016, 87, 978-987.	1.1	109
204	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. <i>BMC Neurology</i> , 2016, 16, 98.	1.8	15
205	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β -1a in MS. <i>Neurology</i> , 2016, 87, 1464-1472.	1.1	28
206	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016, 13, 278.	7.2	23
207	Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. <i>Journal of Neurology</i> , 2016, 263, 1626-1632.	3.6	33
208	Placebo-controlled study in neuromyelitis optica “Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.0	63
209	Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 336-343.	3.5	17
210	Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. <i>Journal of Neuroinflammation</i> , 2016, 13, 48.	7.2	69
211	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
212	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2016, 387, 1075-1084.	13.7	379
213	Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2016, 13, 47-57.	4.4	38
214	<i>Pseudomonas aeruginosa</i> and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes. <i>Infection and Immunity</i> , 2016, 84, 1413-1423.	2.2	16
215	Disease-modifying therapies and infectious risks in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2016, 12, 217-233.	10.1	199
216	Pushing Forward: Remyelination as the New Frontier in CNS Diseases. <i>Trends in Neurosciences</i> , 2016, 39, 246-263.	8.6	82

#	ARTICLE	IF	CITATIONS
217	Long-term (up to 4.5â€¦years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 468-475.	1.9	137
218	Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis. <i>PLoS ONE</i> , 2016, 11, e0164099.	2.5	4
219	Natalizumab restores aberrant mi<scp>RNA</scp> expression profile in multiple sclerosis and reveals a critical role for miRâ€20b. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 43-55.	3.7	71
220	Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth. <i>Journal of Neuroinflammation</i> , 2015, 12, 107.	7.2	16
221	Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. <i>Glia</i> , 2015, 63, 2198-2207.	4.9	99
222	IVlg for relapsingâ€remitting multiple sclerosis: promises and uncertainties. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 419-421.	8.7	15
223	Redox-regulated fate of neural stem progenitor cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 1543-1554.	2.4	37
224	Switching from natalizumab to fingolimod. <i>Neurology</i> , 2015, 85, 29-39.	1.1	110
225	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 756.	9.0	206
226	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	3.0	249
227	A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients â€” A twelve month follow-up. <i>Journal of Neuroimmunology</i> , 2015, 285, 68-70.	2.3	41
228	Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 406-408.	2.0	10
229	Oligodendroglial Maturation Is Dependent on Intracellular Protein Shuttling. <i>Journal of Neuroscience</i> , 2015, 35, 906-919.	3.6	34
230	Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype. <i>Experimental Neurology</i> , 2015, 271, 25-35.	4.1	39
231	PML: The Dark Side of Immunotherapy in Multiple Sclerosis. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 799-801.	8.7	33
232	Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. <i>Clinical Neurophysiology</i> , 2015, 126, 2040-2041.	1.5	14
233	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015, 262, 2466-2471.	3.6	4
234	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015, 52, 848-855.	3.2	34

#	ARTICLE	IF	CITATIONS
235	The neutralizing antibody GNBAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Multiple Sclerosis Journal, 2015, 21, 1200-1203.	3.0	54
236	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology, 2015, 85, 1694-1701.	1.1	55
237	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurology, 2015, 72, 1458.	9.0	130
238	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. Neurology, 2015, 85, 521-527.	1.1	24
239	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology, 2015, 85, 610-618.	1.1	50
240	Hyperglycemia and PPAR γ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. Stroke, 2015, 46, 2935-2942.	2.0	24
241	A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 885-893.	3.0	53
242	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis Journal, 2015, 21, 1036-1044.	3.0	78
243	Alemtuzumab: A new therapy for active relapsing/remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 22-34.	3.0	92
244	FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies. PLoS ONE, 2014, 9, e108756.	2.5	20
245	Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2014, 20, 882-888.	3.0	18
246	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1183-1189.	1.9	73
247	Subtle retinal pathology in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2014, 1, 290-297.	3.7	57
248	The new therapeutic landscape in multiple sclerosis. Current Opinion in Neurology, 2014, 27, 243-245.	3.6	5
249	Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology, 2014, 83, 2153-2157.	1.1	27
250	Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurology, The, 2014, 13, 353-363.	10.2	271
251	Risk evaluation and monitoring in multiple sclerosis therapeutics. Multiple Sclerosis Journal, 2014, 20, 1306-1311.	3.0	23
252	IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Journal of Neuroimmunology, 2014, 274, 225-229.	2.3	36

#	ARTICLE	IF	CITATIONS
253	Thymic Epithelium Determines a Spontaneous Chronic Neuritis in <i>Icam1</i> ^{tm1Jcgr} /NOD Mice. <i>Journal of Immunology</i> , 2014, 193, 2678-2690.	0.8	16
254	Immune regulation of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 3-14.	1.8	28
255	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology</i> , The, 2014, 13, 257-267.	10.2	194
256	Alemtuzumab. <i>Neurology</i> , 2014, 83, 87-97.	1.1	52
257	Interferon beta-1a for multiple sclerosis: old drug, new clothes. <i>Lancet Neurology</i> , The, 2014, 13, 638-639.	10.2	3
258	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1074-1083.	3.0	87
259	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1466-1471.	3.0	58
260	G15â€¦Switch of cerebral A1 adenosine receptor radioligand binding during phenoconversion of Huntington disease: a PET study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A31.1-A31.	1.9	0
261	Plasma exchange: are bigger studies necessarily better?. <i>Nature Reviews Neurology</i> , 2012, 8, 410-410.	10.1	0
262	Volume Transmissionâ€“Mediated Encephalopathies. <i>Archives of Neurology</i> , 2012, 69, 315-21.	4.5	4
263	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet</i> , The, 2012, 380, 1819-1828.	13.7	1,041
264	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet</i> , The, 2012, 380, 1829-1839.	13.7	1,040
265	Advances in the management of multiple sclerosis-related spasticity. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1-1.	2.8	10
266	Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 649-665.	3.1	9
267	Vaccination against infection in patients with multiple sclerosis. <i>Nature Reviews Neurology</i> , 2012, 8, 143-151.	10.1	85
268	Guillainâ€“BarrÃ© Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 2294-2304.	27.0	1,091
269	Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. <i>Clinical Immunology</i> , 2012, 142, 15-24.	3.2	88
270	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	27.8	2,400

#	ARTICLE	IF	CITATIONS
271	Novel treatment for immune neuropathies on the horizon. Journal of the Peripheral Nervous System, 2011, 16, 75-83.	3.1	9
272	Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurology, The, 2011, 10, 293-295.	10.2	27
273	CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Multiple Sclerosis Journal, 2011, 17, 151-156.	3.0	40
274	Natalizumab and Impedance of the Homing of CD34 ⁺ Hematopoietic Progenitors. Archives of Neurology, 2011, 68, 1428.	4.5	30
275	Development of oral cladribine for the treatment of multiple sclerosis. Journal of Neurology, 2010, 257, 163-170.	3.6	40
276	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 402-415.	27.0	1,983
277	Atacept: targeting B cells in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2010, 3, 205-216.	3.5	111
278	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, The, 2009, 8, 987-997.	10.2	322
279	Bleak prospects for primary progressive multiple sclerosis therapy: Downs and downs, but a glimmer of hope. Annals of Neurology, 2009, 66, 429-432.	5.3	23
280	High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opinion on Pharmacotherapy, 2009, 10, 291-309.	1.8	20
281	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 374, 1503-1511.	13.7	551
282	Review: Pathogenesis and treatment of immune-mediated neuropathies. Therapeutic Advances in Neurological Disorders, 2009, 2, 261-281.	3.5	45
283	Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. Journal of Neurology, 2008, 255, 480-487.	3.6	63
284	Advances in the understanding of the mechanism of action of IVIg. Journal of Neurology, 2008, 255, 3-6.	3.6	122
285	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurology, The, 2008, 7, 136-144.	10.2	582
286	The cyclin-dependent kinase inhibitor p57kip2 is a negative regulator of Schwann cell differentiation and <i>in vitro</i> myelination. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8748-8753.	7.1	56
287	Impact of HMG-CoA reductase inhibition on brain pathology. Trends in Pharmacological Sciences, 2007, 28, 342-349.	8.7	56
288	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet, The, 2007, 370, 389-397.	13.7	468

#	ARTICLE	IF	CITATIONS
289	Neutralising antibodies to interferon β in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837.	3.6	48
290	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 2006, 67, 1242-1249.	1.1	684
291	The Pentapeptide QYNAD Does Not Inhibit Neuronal Network Activity. Canadian Journal of Neurological Sciences, 2005, 32, 344-348.	0.5	6
292	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology, 2005, 58, 840-846.	5.3	4,495
293	Anti- α 4 integrin therapy for multiple sclerosis. Neurology, 2005, 64, 1336-1342.	1.1	286
294	Clinical Stabilization and Effective B-Lymphocyte Depletion in the Cerebrospinal Fluid and Peripheral Blood of a Patient With Fulminant Relapsing-Remitting Multiple Sclerosis. Archives of Neurology, 2005, 62, 1620-3.	4.5	124
295	Immune mechanisms in neurological disease. , 2002, , 1501-1526.		1
296	Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology, 2002, 59, 909-913.	1.1	165
297	Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet, The, 2002, 360, 2018-2025.	13.7	870
298	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, The, 2001, 357, 1576-1582.	13.7	1,025
299	Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 2001, 50, 121-127.	5.3	6,122
300	The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Annals of Neurology, 1990, 27, 247-257.	5.3	115
301	Macrophages but not schwann cells express ia antigen in experimental autoimmune neuritis. Annals of Neurology, 1990, 28, 70-77.	5.3	51
302	Substance P, the Immune System and Inflammation. International Reviews of Immunology, 1989, 4, 229-249.	3.3	35
303	The blood-nerve barrier in Wallerian degeneration: A sequential long-term study. Muscle and Nerve, 1989, 12, 627-635.	2.2	74
304	Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase. Annals of Neurology, 1988, 23, 453-460.	5.3	90
305	Immune Mechanisms in Inflammatory Polyneuropathy. Annals of the New York Academy of Sciences, 1988, 540, 122-161.	3.8	88
306	Suppression of P2-T-Cell Line Mediated Experimental Autoimmune Neuritis by Interleukin-2 Receptor Blockade. Annals of the New York Academy of Sciences, 1988, 540, 563-565.	3.8	1

#	ARTICLE	IF	CITATIONS
307	Adoptive Transfer Experimental Autoimmune Encephalomyelitis.. Annals of the New York Academy of Sciences, 1988, 540, 738-740.	3.8	0
308	Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism. FASEB Journal, 1988, 2, 48-51.	0.5	96
309	Chemically modified low density lipoproteins as inducers of enzyme release from macrophages. FEBS Letters, 1985, 186, 211-214.	2.8	30
310	Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. FEBS Letters, 1983, 160, 209-212.	2.8	74